157 734

Cited 49 times in

Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)

DC Field Value Language
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.date.accessioned2022-05-09T17:22:20Z-
dc.date.available2022-05-09T17:22:20Z-
dc.date.issued2022-04-
dc.identifier.issn1542-3565-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/188530-
dc.description.abstractBackground & aims: Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels of hepatitis B core-related antigen (HBcrAg) and hepatitis B surface antigen (HBsAg) and outcome after therapy cessation. Methods: Patients who discontinued NA therapy in centers in Asia and Europe were enrolled. HBcrAg and HBsAg were measured at treatment cessation, and associations with off-treatment outcomes were explored. The SCALE-B (Surface antigen, Core-related antigen, Age, ALT, and tenofovir for HBV) score was calculated as previously reported. End points included sustained virologic response (VR; hepatitis B virus DNA level <2000 IU/mL), HBsAg loss, and alanine aminotransferase (ALT) flares (>3× upper limit of normal). Re-treated patients were considered nonresponders. Results: We analyzed 572 patients, 457 (80%) were Asian and 95 (17%) were hepatitis B e antigen positive at the start of NA therapy. The median treatment duration was 295 weeks. VR was observed in 267 (47%), HBsAg loss was observed in 24 (4.2%), and ALT flare was observed in 92 (16%). VR (67% vs 42%) and HBsAg loss (15% vs 1.5%) was observed more frequently in non-Asian patients when compared to Asian patients (P < .001). Lower HBcrAg levels were associated with higher rates of VR (odds ratio [OR], 0.701; P < .001) and HBsAg loss (OR, 0.476; P < .001), and lower rates of ALT flares (OR, 1.288; P = .005). Similar results were observed with HBsAg (VR: OR, 0.812; P = .011; HBsAg loss: OR, 0.380; P < .001; and ALT flare: OR, 1.833; P < .001). Lower SCALE-B scores were associated with higher rates of VR, HBsAg loss, and lower rates of ALT flares in both Asian and non-Asian patients (P < .001). Conclusions: In this multicenter study, off-treatment outcomes after NA cessation varied with ethnicity. Lower levels of HBcrAg and HBsAg were associated with favorable outcomes. A risk score comprising both factors can be used for risk stratification.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherW.B. Saunders-
dc.relation.isPartOfCLINICAL GASTROENTEROLOGY AND HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntiviral Agents / therapeutic use-
dc.subject.MESHDNA, Viral-
dc.subject.MESHHepatitis B Core Antigens-
dc.subject.MESHHepatitis B Surface Antigens*-
dc.subject.MESHHepatitis B virus / genetics-
dc.subject.MESHHepatitis B, Chronic*-
dc.subject.MESHHumans-
dc.titlePrediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMilan J Sonneveld-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorApichat Kaewdech-
dc.contributor.googleauthorWai-Kay Seto-
dc.contributor.googleauthorYasuhito Tanaka-
dc.contributor.googleauthorIvana Carey-
dc.contributor.googleauthorMargarita Papatheodoridi-
dc.contributor.googleauthorFlorian van Bömmel-
dc.contributor.googleauthorThomas Berg-
dc.contributor.googleauthorFabien Zoulim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorGeorge N Dalekos-
dc.contributor.googleauthorNicole S Erler-
dc.contributor.googleauthorChristoph Höner Zu Siederdissen-
dc.contributor.googleauthorHeiner Wedemeyer-
dc.contributor.googleauthorMarkus Cornberg-
dc.contributor.googleauthorMan-Fung Yuen-
dc.contributor.googleauthorKosh Agarwal-
dc.contributor.googleauthorAndre Boonstra-
dc.contributor.googleauthorMaria Buti-
dc.contributor.googleauthorTeerha Piratvisuth-
dc.contributor.googleauthorGeorge Papatheodoridis-
dc.contributor.googleauthorBenjamin Maasoumy-
dc.identifier.doi10.1016/j.cgh.2020.12.005-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.relation.journalcodeJ02981-
dc.identifier.eissn1542-7714-
dc.identifier.pmid33309804-
dc.subject.keywordHBcrAg-
dc.subject.keywordHBsAg-
dc.subject.keywordSCALE-B-
dc.subject.keywordSustained Response-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.citation.volume20-
dc.citation.number4-
dc.citation.startPagee784-
dc.citation.endPagee793-
dc.identifier.bibliographicCitationCLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.20(4) : e784-e793, 2022-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.